HPV DNA Testing for Cervical Cancer Screening

International Journal of Gynecology and Obstetrics

Volumn 95, Issue SUPPL. 1, 2006, Pages

  WRIGHT Jr , Thomas C ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; cytology; human papillomavirus; prevention

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CARCINOGENIC ACTIVITY; COMPARATIVE STUDY; CRYOTHERAPY; CYTOLOGY; DNA REPLICATION; DNA SCREENING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; LABORATORY TEST; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 33845223831     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(06)60039-8     Document Type: Article

References (44)

1. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006)
2. Cervical Cancer Facts and Figures 2006. In: American Cancer Society, 2006.
3. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 3 (2005) 481-488
4. Munoz N., Bosch F., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
5. Munoz N., Castellsague X., De Gonzalez A., et al. HPV in the etiology of human cancer. Vaccine (2006)
6. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184 (1991) 9-13
7. Bosch F., Lorincz A., Munoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
8. Bosch F., and de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
9. Human Papillomaviruses (2005), IARC, Lyon
10. Walboomers J., Jacobs M., Manos M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
11. Bosch F., Manos M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 779-780
12. Clifford G., Smith J., Plummer M., et al. Papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88 1 (2003) 63-73
13. Rossouw J., Anderson G., Prentice R., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
14. Woodman C., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357 9271 (2001) 1831-1836
15. Sherman M., Lorincz A., Scott D., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 95 1 (2003) 46-52
16. Khan M., Castle P., Lorincz A., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 14 (2005) 1072-1079
17. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 5 (2002) 342-350
18. Munger K., and Howley P. Human papillomavirus immortalization and transformation functions. Virus Research 89 2 (2002) 213-228
19. Horner S., DeFilippis R., Manuelidis L., et al. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 78 8 (2004) 4063-4073
20. Durst M., Glitz D., Schneider A., et al. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization. Virology 189 1 (1992) 132-140
21. Stoler M., Rhodes C., Whitbeck A., et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23 2 (1992) 117-128
22. Brown D., Shew M., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 2 (2005) 182-192
23. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 6 (2003) 485-490
24. Winer R., Lee S., Hughes J., et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 3 (2003) 218-226
25. Moscicki A., Schiffman M., Kjaer S., et al. Updating the natural history of HPV and anogenital cancer. Vaccine (2006)
26. Schiffman M., and Kjaer S. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
27. Cervix Cancer Screening (2005), IARC, Lyon
28. Cuzick J., Clavel C., Petry K., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 5 (2006) 1095-1101
29. Bigras G., and de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: Results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 93 5 (2005) 575-581
30. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: Results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98 11 (2006) 765-774
31. Belinson J., Qiao Y., Pretorius R., et al. Shanxi province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 83 2 (2001) 439-444
32. Herrero R., Hildesheim A., Bratti C., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92 6 (2000) 464-474
33. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362 9399 (2003) 1871-1876
34. Salmeron J., Lazcano-Ponce E., Lorincz A., et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14 6 (2003) 505-512
35. Petry K., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8466 patients. Br J Cancer 88 10 (2003) 1570-1577
36. Wright Jr. T., Denny L., Kuhn L., et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283 1 (2000) 81-86
37. Kinney W. Use of HPV DNA testing for primary cervical cancer screening in Kaiser Northern California. In: American Society of Colposcopy and Cervical Pathology Biennial Meeting; 2006; Las Vegas, NV.; 2006.
38. Wright Jr. T., Schiffman M., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 2 (2004) 304-309
39. Human Papillomavirus (2005), American College of Obstetricians and Gynecologists, Washington, DC Report No.: 61.
40. Goldie S., Kim J., and Wright T. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103 4 (2004) 619-631
41. Denny L., Kuhn L., De Souza M., et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: A randomized controlled trial. JAMA 294 17 (2005) 2173-2181
42. Richart R. Screening; The next century. Cancer 76 (1995) 1919-1927
43. Goldie S., Kuhn L., Denny L., et al. Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness. JAMA 285 24 (2001) 3107-3115
44. Goldie S., Gaffikin L., Goldhaber-Fiebert J., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 20 (2005) 2158-2168